{"id":"atripla-or-stribild","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Dizziness or CNS effects"},{"rate":"10-20","effect":"Nausea"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Rash"},{"rate":"5-15","effect":"Renal impairment or proteinuria"},{"rate":"variable","effect":"Bone density loss"}]},"_chembl":{"chemblId":"CHEMBL5970128","moleculeType":null,"molecularWeight":"607.73"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atripla combines efavirenz (a non-nucleoside reverse transcriptase inhibitor), emtricitabine (a nucleoside reverse transcriptase inhibitor), and tenofovir (a nucleotide reverse transcriptase inhibitor) to block HIV reverse transcriptase. Stribild combines elvitegravir (an integrase strand transfer inhibitor), emtricitabine, and tenofovir to target both integrase and reverse transcriptase. Both regimens work synergistically to suppress HIV viral replication and reduce viral load.","oneSentence":"Atripla and Stribild are fixed-dose combination antiretroviral drugs that inhibit HIV replication through multiple mechanisms targeting reverse transcriptase and integrase.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:19:26.531Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve and treatment-experienced patients (Atripla)"},{"name":"HIV-1 infection in treatment-naïve patients (Stribild)"}]},"trialDetails":[{"nctId":"NCT01815580","phase":"PHASE4","title":"HIV Test and Treat to Prevent HIV Transmission Among MSM and Transgender Women","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2013-07","conditions":"HIV","enrollment":225},{"nctId":"NCT01815736","phase":"PHASE3","title":"Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-03-27","conditions":"HIV, HIV Infections","enrollment":1443},{"nctId":"NCT02246998","phase":"PHASE4","title":"Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-12-15","conditions":"HIV-1 Infection","enrollment":72}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16252,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["(alternate: Truvada + 3rd ARV)"],"phase":"marketed","status":"active","brandName":"Atripla or Stribild","genericName":"Atripla or Stribild","companyName":"Fred Hutchinson Cancer Center","companyId":"fred-hutchinson-cancer-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Atripla and Stribild are fixed-dose combination antiretroviral drugs that inhibit HIV replication through multiple mechanisms targeting reverse transcriptase and integrase. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients (Atripla), HIV-1 infection in treatment-naïve patients (Stribild).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}